268
Participants
Start Date
January 22, 2018
Primary Completion Date
October 20, 2020
Study Completion Date
September 5, 2023
Dolutegravir
Patients randomized to the study drug will be commenced on an antiretroviral regimen comprising DTG 50mg once daily in combination with 2 NRTIs
Standard of Care (EFV + 2 NRTI backbone)
Patients randomized to receive standard of care will receive the currently used antiretroviral regimens in keeping with national policy.
University of Cape Town, Cape Town
Infectious Diseases Institute, Kampala
UNITAID
OTHER
University of Cape Town
OTHER
Liverpool School of Tropical Medicine
OTHER
Infectious Diseases Institute, Uganda
OTHER
Radboud University Medical Center
OTHER
University of Liverpool
OTHER